Phase II Trial of Exemestane in Combination With Fulvestrant in Postmenopausal Women With Advanced, Hormone-Responsive Breast Cancer

Clinical Breast Cancer - United States
doi 10.1016/j.clbc.2012.01.003
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2014English

Phase I Trial of Exemestane in Combination With Metformin and Rosiglitazone in Nondiabetic Obese Postmenopausal Women With Hormone Receptor–positive Metastatic Breast Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2012English

A Randomized Trial of Combination Anastrozole Plus Gefitinib and of Combination Fulvestrant Plus Gefitinib in the Treatment of Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer

Breast Cancer Research and Treatment
Cancer ResearchOncology
2012English

Review of Hormone-Based Treatments in Postmenopausal Patients With Advanced Breast Cancer Focusing on Aromatase Inhibitors and Fulvestrant

ESMO Open
Cancer ResearchOncology
2016English

Phase 1b Study of Orteronel in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic Breast Cancer

Investigational New Drugs
OncologyPharmacology
2016English

A Phase II Trial of Erlotinib in Combination With Bevacizumab in Patients With Metastatic Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2008English

Phase II Trial of Dexverapamil and Epirubicin in Patients With Non-Responsive Metastatic Breast Cancer

British Journal of Cancer
Cancer ResearchOncology
1998English

Cost Effectiveness of Fulvestrant 500 Mg in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer in the UK

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Palbociclib With Letrozole in Postmenopausal Women With ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‐2 Trial

Oncologist
Cancer ResearchMedicineOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy